Clinical use of Haemate® P in von Willebrand disease: A 25-year retrospective observational study

Thrombosis Research

Volumn 135, Issue 3, 2015, Pages 479-484

  Miesbach, Wolfgang ^a   Krekeler, Stefanie ^a   Wolf, Zsuzsanna ^a   Seifried, Erhard ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

Factor VIII; Haemate; Haemophilia A; Humate von; von Willebrand factor; Willebrand disease

Indexed keywords

BLOOD CLOTTING FACTOR 8 PLUS VON WILLEBRAND FACTOR; DESMOPRESSIN; HEMOGLOBIN; BLOOD CLOTTING FACTOR 8; DRUG COMBINATION; FACTOR VIII, VON WILLEBRAND FACTOR DRUG COMBINATION; HEMOSTATIC AGENT; VON WILLEBRAND FACTOR;

ADULT; AGED; ARTICLE; BLADDER BLEEDING; BLEEDING; BRAIN HEMORRHAGE; DISEASE SEVERITY; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG SAFETY; DRUG TOLERABILITY; EPISTAXIS; FEMALE; FOLLOW UP; GINGIVA BLEEDING; HEMARTHROSIS; HEMATURIA; HEMOPHILIA A; HEPATITIS A; HEPATITIS B; HEPATITIS C; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MENORRHAGIA; MIDDLE AGED; MUSCLE BLEEDING; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; THROMBOEMBOLISM; TRANSURETHRAL RESECTION; TREATMENT DURATION; VON WILLEBRAND DISEASE; WOUND HEALING; DRUG COMBINATION; VERY ELDERLY; VON WILLEBRAND DISEASES;

ADULT; AGED; AGED, 80 AND OVER; DRUG COMBINATIONS; FACTOR VIII; FEMALE; HEMOSTATICS; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; VON WILLEBRAND DISEASES; VON WILLEBRAND FACTOR;

EID: 84925794639     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2014.12.017     Document Type: Article

References (19)

1. M. Franchini, and G. Lippi The role of von Willebrand factor in hemorrhagic and thrombotic disorders Crit Rev Clin Lab Sci 44 2007 115 149
2. U. Budde, and R. Schneppenheim Von Willebrand factor and von Willebrand disease Rev Clin Exp Hematol 5 2001 335 368
3. R. Schneppenheim, and U. Budde von Willebrand factor: the complex molecular genetics of a multidomain and multifunctional protein J Thromb Haemost 9 Suppl. 1 2011 209 215
4. E.J. Favaloro Von Willebrand disease: local diagnosis and management of a globally distributed bleeding disorder Semin Thromb Hemost 37 2011 440 455
5. W.L. Nichols, M.B. Hultin, A.H. James, M.J. Manco-Johnson, R.R. Montgomery, and T.L. Ortel von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA) Haemophilia 14 2008 171 232
6. J.E. Sadler, U. Budde, J.C. Eikenboom, E.J. Favaloro, F.G. Hill, and L. Holmberg Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor J Thromb Haemost 4 2006 2103 2114
7. E.J. Favaloro, M. Franchini, and G. Lippi Biological therapies for von Willebrand disease Expert Opin Biol Ther 12 2012 551 564
8. E. Berntorp Human plasma von Willebrand factor/factor VIII complex (Haemate P/Humate-P) in von Willebrand disease and haemophilia A: a viewpoint by Eric Berntorp Drugs 67 2007 1520
9. A. Dobrkovska, U. Krzensk, and J.R. Chediak Pharmacokinetics, efficacy and safety of Humate-P in von Willebrand disease Haemophilia 4 Suppl. 3 1998 33 39
10. A.R. Thompson, J.C. Gill, B.M. Ewenstein, G. Mueller-Velten, and B.A. Schwartz Successful treatment for patients with von Willebrand disease undergoing urgent surgery using factor VIII/VWF concentrate (Humate-P) Haemophilia 10 2004 42 51
11. J.C. Gill, B.M. Ewenstein, A.R. Thompson, G. Mueller-Velten, and B.A. Schwartz Successful treatment of urgent bleeding in von Willebrand disease with factor VIII/VWF concentrate (Humate-P): use of the ristocetin cofactor assay (VWF:RCo) to measure potency and to guide therapy Haemophilia 9 2003 688 695
12. J.C. Gill, A. Shapiro, L.A. Valentino, J. Bernstein, C. Friedman, and W.L. Nichols von Willebrand factor/factor VIII concentrate (Humate-P) for management of elective surgery in adults and children with von Willebrand disease Haemophilia 17 2011 895 905
13. P. Mannuccio Mannucci, P.A. Kyrle, S. Schulman, J. Di Paola, R. Schneppenheim, and Gill J. Cox Prophylactic efficacy and pharmacokinetically guided dosing of a von Willebrand factor/factor VIII concentrate in adults and children with von Willebrand's disease undergoing elective surgery: a pooled and comparative analysis of data from USA and European Union clinical trials Blood Transfus 11 2013 533 540
14. S. Halimeh, A. Krumpel, H. Rott, N. Bogdanova, U. Budde, and D. Manner Long-term secondary prophylaxis in children, adolescents and young adults with von Willebrand disease. Results of a cohort study Thromb Haemost 105 2011 597 604
15. S. Lethagen Clinical experience of prophylactic treatment in von Willebrand disease Thromb Res 118 Suppl. 1 2006 S9 S11
16. A. Groner Pathogen safety of plasma-derived products - Haemate P/Humate-P Haemophilia 14 Suppl. 5 2008 54 71
17. E. Raquet, M. Stockschlader, and G. Dickneite Repeated infusions of VWF/FVIII concentrate: impact of VWF:FVIII ratio on FVIII trough and peak levels in a rabbit model Haemophilia 17 2011 808 814
18. J. Goudemand, C. Negrier, N. Ounnoughene, and Y. Sultan Clinical management of patients with von Willebrand's disease with a VHP vWF concentrate: the French experience Haemophilia 4 Suppl. 3 1998 48 52
19. Board of the German Medical Council on the recommendation of the Scientific Advisory Board Querschnitts-Leitlinien (BÄK) zur Therapie mit Blutkomponenten und Plasmaderivaten. 4. Auflage 2008 2008 [Available from: http://www.bundesaerztekammer.de/downloads/Querschnittsleitlinie-Gesamtdokument-deutsch-07032011.pdf [Accessed December 2014]]